Humanin: Side Effects & Safety

As an endogenously produced mitochondrial peptide, humanin is expected to have favorable biocompatibility. Animal studies have not reported significant adverse effects. However, no human clinical trials have been conducted, and long-term safety is entirely unknown.

• No significant toxicity reported in published animal studies
• Injection site reactions: Expected with any subcutaneous peptide injection
• Endogenous peptide: Naturally produced by human cells, suggesting biological compatibility

All safety data is preclinical. The effects of sustained exogenous humanin supplementation — particularly its anti-apoptotic effects — on cancer surveillance, immune function, and tissue homeostasis are unknown. Humanin inhibits BAX-mediated apoptosis, raising theoretical questions about cancer cell survival.

• Active cancer (anti-apoptotic effects could theoretically protect cancer cells)
• Pregnancy and breastfeeding (no safety data)
• No known drug interactions established